Transcatheter mitral valve replacement is wrenching the spotlight away from the repair devices that grabbed the headlines last summer.
Venture capital firms invested a record $16.8bn in private drug developers globally in 2018, but signs of a cooling are clear.
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.
Private biotechs received almost $4bn in venture financing in the third quarter, as the healthy financing climate showed few signs of deteriorating.
Chi-Med is not alone in seeing Chinese approval as the prelude to a regulatory green light in the west.
As the tiny Norwegian biotech gears up to put its first asset into the clinic, investors could use an ongoing trial to handicap its chances of success.
Immunocore has recently been beset with multiple senior executive departures, but has managed to press on into phase I with a Glaxo-partnered asset.
Which groups might Boston Scientific bolt on next?
Sequencing data is all well and good, but what does it mean?